A Brief Cognitive Task Intervention for NHS Staff Affected by COVID-19 Trauma (GAINS-2 Study) (GAINS-2)

April 30, 2026 updated by: P1vital Products Limited

A Randomised Controlled Trial of a Brief Cognitive Task Intervention to Support NHS Staff Experiencing Intrusive Memories of Traumatic Events From Working in the COVID- 19 Pandemic.

Frontline healthcare staff are frequently exposed to traumatic events at work (e.g., witnessing patients die), amplified by the COVID-19 pandemic. A significant proportion experience intrusive memories of these events that pop suddenly into mind: they can disrupt functioning and can contribute to post-traumatic stress disorder. Previous research has shown that a brief behavioural intervention can reduce the number of intrusive memories after a traumatic event. In this study we will test the effect of a digital imagery-competing task, a digital music-listening task and treatment as usual (TAU) for National Health Service (NHS) staff with intrusive memories of work-related traumatic events from the pandemic. We test the effect on the number of intrusive memories (primary outcome), and other clinical symptoms (PTSD, anxiety, depression, and insomnia), in addition to work functioning, general functioning and quality of life (secondary outcomes). Intervention feasibility, acceptability and implementation will also be explored (additional outcomes). We will recruit approximately 150 NHS staff (via the Intensive Care Society, social media and direct advertising by NHS Trusts) with intrusive memories of traumatic events experienced during the COVID-19 pandemic.

The study is funded by the Wellcome Trust (223016/Z/21/Z).

Study Overview

Detailed Description

A statistical analysis plan will be prepared prior to the first interim analysis using Bayesian analyses for statistical inference.

Regular monitoring will be performed by P1vital Products to verify that the study is conducted, and data are generated, documented and reported in compliance with the protocol, GCP and the applicable regulatory requirements. Quality assurance representatives from the Sponsor may carry out an audit of the study in compliance with regulatory guidelines and relevant standard operating procedures.

Study Type

Interventional

Enrollment (Actual)

122

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oxfordshire
      • Wallingford, Oxfordshire, United Kingdom, OX10 8BA
        • P1vital Products Ltd

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Aged 18 or above.
  • Able to read, write and speak in English.
  • Worked in a clinical role with COVID-19 patients in the NHS during the COVID-19 pandemic.
  • Experienced at least one traumatic event related to their clinical work during the COVID- 9 pandemic meeting criterion A of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for Post-Traumatic Stress Disorder (PTSD): "exposure to actual or threatened death, serious injury, or sexual violence" by "directly experiencing the traumatic event(s)" or "witnessing, in person, the event(s) as it occurred to others".
  • Experience intrusive memories of the traumatic event(s).
  • Experienced at least three intrusive memories in the week prior to screening.
  • Have internet access.
  • Willing and able to provide informed consent and complete study procedures
  • Willing and able to be contacted by the research team during the study period.
  • Have not taken part in a previous study of this intervention from this research team

Exclusion Criteria:

• Have fewer than three intrusive memories during the run-in week.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Brief digital imagery-competing task
Access to a brief digital imagery-competing task for 24 weeks (first 4 weeks with optional researcher support).

First session guided by a researcher: A memory cue followed by playing a computer game with mental rotation instructions.

Option to engage in self-administered/guided sessions after the first session.

Experimental: Brief digital music-listening task
Access to a brief digital music-listening task for 24 weeks (first 4 weeks with optional researcher support).

First session guided by a researcher: Information about the composer's music followed by listening to classical music.

Option to engage in self-administered/guided sessions after the first session.

Experimental: Treatment As Usual
Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events for 24 weeks.
Access to routine care that participants would otherwise receive if having intrusive memories of traumatic events.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Intrusive Memories of Traumatic Event(s)
Time Frame: Run-in/screening week, Week 4 (all arms)
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
Run-in/screening week, Week 4 (all arms)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep Condition Indicator (SCI)
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 2-item scale measures sleep problems against the DSM-5 criteria for insomnia disorder. Item responses are each scored 0-4, with scores from 0 to 2 indicating threshold criteria for insomnia disorder. Total score ranges 0-8, with a higher score indicating better sleep.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Number of Intrusive Memories of Traumatic Event(s)
Time Frame: Run-in/Screening week, Weeks 12 and 24 (all arms)
Number of intrusive memories of traumatic event(s) recorded by participants in a brief daily online diary for 7 days.
Run-in/Screening week, Weeks 12 and 24 (all arms)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 20-item measure assesses symptoms of PTSD over the last week. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). Scores are summed to give a total severity score (ranging 0 to 80), with greater scores indicating greater symptom severity.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Generalised Anxiety Disorder 2-item Scale (GAD-2)
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 2-item short-form self-report measure assesses symptoms of anxiety. Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day"). Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Patient Health Questionnaire 2-item Version (PHQ-2)
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 2-item short-form self-report measure assesses symptoms of depression. Items are rated for how often they have bothered the respondent over the last two weeks, from 0 ("not at all") to 3 ("nearly every day"). Total score is the sum of both items and ranges from 0 to 6, with greater scores indicating greater symptom severity.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Scale of Work Engagement and Burnout (SWEBO) - Work Engagement Total Score
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 19-item self-report measure assesses work engagement and burnout. The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication). The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness). Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time). The work engagement subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work engagement.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Scale of Work Engagement and Burnout (SWEBO) - Work Burnout Total Score
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
This 19-item self-report measure assesses work engagement and burnout. The work engagement subscale consists of 10 items assessing three dimensions (vigour, attentiveness, dedication). The burnout subscale consists of 9 items assessing three dimensions (exhaustion, disengagement and inattentiveness). Respondents rate how often they have felt each descriptive in the past two weeks, from 1 (not at all) to 4 (all the time). The work burnout subscale total score is calculated as a mean of items (range 1-4), with greater scores indicating greater work burnout.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Sickness Absence
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Single item assessing self-reported number of sick days taken from work in the last 4 weeks.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Intention to Leave Job
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
3 items assess participants' intention to leave their job e.g. "I think a lot about leaving the job", each rated from 1 (strongly agree) to 5 (strongly disagree). The total score ranges 3 to 15, with a lower score indicating stronger intention to leave the job.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Mobility
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status. Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale. The mobility item is scored on a 5-point ordinal scale from "I have no problems in walking about" to "I am unable to walk about".
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Self Care
Time Frame: Baseline, Week 4, Week 12 and Week 24
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status. Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale. The self care item is scored on a 5-point ordinal scale from "I have no problems washing or dressing myself" to "I am unable to wash or dress myself".
Baseline, Week 4, Week 12 and Week 24
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Usual Activities
Time Frame: Baseline, Week 4, Week 12 and Week 24
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status. Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale. The usual activities item is scored on a 5-point ordinal scale from "I have no problems doing my usual activities" to "I am unable to do my usual activities".
Baseline, Week 4, Week 12 and Week 24
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Pain / Discomfort
Time Frame: Baseline, Week 4, Week 12 and Week 24
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status. Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale. The pain / discomfort item is scored on a 5-point ordinal scale from "I have no pain or discomfort" to "I have extreme pain or discomfort".
Baseline, Week 4, Week 12 and Week 24
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Anxiety / Depression
Time Frame: Baseline, Week 4, Week 12 and Week 24
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief, five-item measure for assessing general quality of life and health status. Items assess mobility, self-care, usual activities, pain/discomfort and anxiety/depression each on a 5-point scale. The anxiety / depression item is scored on a 5-point ordinal scale from "I am not anxious or depressed" to "I am extremely anxious or depressed".
Baseline, Week 4, Week 12 and Week 24
5-level European Quality of Life 5 Dimension (EQ-5D-5L), Overall Health
Time Frame: Baseline, Week 4, Week 12 and Week 24
The 5-level version of the EuroQol-5D (EQ-5D-5L) is a brief measure for assessing general quality of life and health status. Respondents rate their overall health today on a visual analogue scale from 0 (the worst health you can imagine) to 100 (the best health you can imagine).
Baseline, Week 4, Week 12 and Week 24
World Health Organization Disability Assessment Schedule 12-item Version (WHODAS 2.0)
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
The 12-item, self-report version of the WHODAS 2.0 will be used to assess difficulties in relation to the impact of intrusive memories. Respondents rate how much difficulty they have had in each area in the past 30 days, from 0 (none) to 4 (extreme or cannot do). The overall score is calculated as a percentage of the maximum possible score (i.e., 48 points), with greater scores indicating greater impairment.
Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Intrusive Memory Ratings: Item 1. Approximately How Often Did Intrusive Memories of the Traumatic Event Pop Into Your Mind?
Time Frame: Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)

This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)).

Here we present Item 1 assessing the frequency of intrusive memories on a 7-point scale from 'never' to 'many times a day'. Other items from this questionnaire are presented below.

Baseline, 4 weeks, 12 weeks and 24 weeks (all arms)
Intrusive Memory Ratings: Item 4a. Duration of Interference
Time Frame: Baseline, Week 4, Week 12 and Week 24 (all arms)

This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)).

Here we present Item 4a assessing the for how long intrusive memories interfered with what participants were doing on a 7-point scale from '<1 min' to '>60 mins'. Other items from this questionnaire are presented below.

Baseline, Week 4, Week 12 and Week 24 (all arms)
Intrusive Memory Ratings: Distress (Item 2), Disruption to Concentration (Item 3), Interference (Item 4), Impact on Work Functioning (Item 5), and Impact on Functioning in Other Areas of Life (Item 7)
Time Frame: Baseline, Week 4, Week 12 and Week 24 (all arms)

This questionnaire assesses a number of intrusive memories characteristics, including frequency (Item 1: 7-point categorical response from 'never' to 'many times a day'); distress (Item 2: 0=not at all to 10=extremely); disruption to concentration (Item 3: 0=not at all to 10=extremely); interference (Item 4: how much (0=not at all to 10=extremely), and Item 4a: for how long (6-point response from '<1min' to '>60mins')); impact on work functioning (Item 5: how much (0=not at all to 10=extremely) and Item 6: in what ways (open text response)); impact on functioning in other areas of life (Item 7: how much (0=not at all to 10=extremely) and in what ways (Item 8: open text response)).

Here we present data for the five items scored on an 11-point scale (0=not at all to 10=extremely) assessing distress (Item 2), disruption to concentration (Item 3), interference (Item 4), impact on work functioning (Item 5), and impact on functioning in other areas of life (Item 7).

Baseline, Week 4, Week 12 and Week 24 (all arms)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes to Health and Work - Dichotomous Outcomes
Time Frame: 4 weeks, 12 weeks and 24 weeks (all arms)
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g. relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment. Dichotomous outcomes are presented below, and discrete outcomes with count data are presented under "Changes to health and work - discrete outcomes".
4 weeks, 12 weeks and 24 weeks (all arms)
Changes to Health and Work - Discrete Outcomes
Time Frame: 4 weeks, 12 weeks and 24 weeks (all arms)
The 9-item questionnaire will be used to assess the occurrence and number of any new traumatic events, any additional stressful life events (e.g. relationship problems, financial problems), new treatments received, untoward medical occurrences, changes to the job, or changes to the number of hours worked per week since the last assessment. Discrete outcomes are presented below, and dichotomous outcomes are presented under "Changes to health and work - dichotomous outcomes".
4 weeks, 12 weeks and 24 weeks (all arms)
Feedback Questionnaire
Time Frame: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
A 12-item questionnaire assessing participants' experience of using the brief cognitive task. The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very). The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cogntive task, both with an open response.
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
Feedback Questionnaire (Total Score)
Time Frame: After 4 weeks (brief imagery-competing task and brief music listening task arms only)
A 12-item questionnaire assessing participants' experience of using the brief cognitive task. The first ten items assess how easy, helpful, distressing, burdensome and acceptable participants found the brief cognitive task, how willing they would be to use it in the future, how confident they would be in recommending it to a friend and how much they feel it could be used to support staff within the NHS, each rated from 0 (not at all) to 10 (very); items for distress and burden are reverse scored from 0 (very) to 10 (not at all). The last two items ask how the brief cognitive task could be improved, and for any other comments or suggestions about the brief cognitive task, both with an open response. A total score of the eight categorical items is presented (range 0 - 80), with greater scores indicating more favourable feedback towards the allocated digital task.
After 4 weeks (brief imagery-competing task and brief music listening task arms only)
Optional Qualitative Interview
Time Frame: Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
This semi-structured interview will consist of a number of questions designed to gain an in-depth understanding of participants' experience of using the brief cognitive task, including acceptability, improvement suggestions, and potential barriers/facilitators to implementation.
Week 4 and Week 24 (brief imagery competing task and brief music listening task arms only)
Weekly Work Pattern, Number of Days Worked
Time Frame: Baseline, Week 4, Week 12 and Week 24
One item asses the number of days worked in the last week (both with responses from 0 to 7 days).
Baseline, Week 4, Week 12 and Week 24
Weekly Work Pattern, Number of Night Shifts Worked
Time Frame: Baseline, Week 4, Week 12 and Week 24
One item asses the number of night shifts worked in the last week (both with responses from 0 to 7).
Baseline, Week 4, Week 12 and Week 24
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Categorical Items
Time Frame: Day 0 (post-randomisation)
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items. Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very"). Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items. CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect. Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
Day 0 (post-randomisation)
Expectancy of Intervention Effect (Credibility and Expectancy Questionnaire, CEQ) - Total Score
Time Frame: Day 0 (post-randomisation)
The Credibility and Expectancy Questionnaire (CEQ) consists of 6 items. Items 1, 2, 3, and 5 were assessed on a 9-point integer scale ranging from 1 ("not at all") to 9 ("very"). Items 4 and 6 were assessed on an 11-point scale (response range of 0-100%) and, for comparability, were converted to the same 9-point scale as other items. CEQ total score was calculated by summing all six items producing a possible total score range of 6-54; with greater scores indicating greater credibility and expectancy of intervention effect. Participants completed the Credibility and Expectancy Questionnaire (CEQ) after being informed of treatment allocation (Day 0).
Day 0 (post-randomisation)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Emily Holmes, Uppsala University (UU), Sweden
  • Principal Investigator: Amy Beckenstrom, P1vital Products, Wallingford

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 8, 2022

Primary Completion (Actual)

October 30, 2023

Study Completion (Actual)

March 19, 2024

Study Registration Dates

First Submitted

November 11, 2022

First Submitted That Met QC Criteria

November 11, 2022

First Posted (Actual)

November 15, 2022

Study Record Updates

Last Update Posted (Actual)

May 27, 2026

Last Update Submitted That Met QC Criteria

April 30, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P1V-GAINS-IN02

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The Study Protocol and Statistical Analysis Plan will be shared on the Open Science Framework, together with an anonymised database of individual participant data, data dictionary, and analysis scripts.

IPD Sharing Time Frame

The Study Protocol and Statistical Analysis Plan were uploaded to the Open Science Framework (OSF) prior to the last participant completing the last visit.

Results of the study will be shared through open access publications. On publication of the main study results, the associated database of individual participant data (anonymised), data dictionary, and analysis scripts will be made available on OSF.

The information described above will be shared indefinitely and with no end date on the OSF platform.

IPD Sharing Access Criteria

The information described above will be made available on the OSF indefinitely.

OSF is an open source web application that is freely accessible to the public and scientific community.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intrusive Memories of Traumatic Event(s)

Clinical Trials on Brief digital imagery-competing task

Subscribe